Zebra Capital Management’s Fennec Pharmaceuticals FENC Stock Holding History

Zebra Capital Management’s Portfolio FENC Stock Details FENC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-17,568	Closed	-$85K	–	477
2019 Q1	$85K	Hold	17,568	–	–	0.05%	422
2018 Q4	$112K	Buy	+17,568	New	+$123K	0.07%	352

Other funds holding FENC

Southpoint Capital Advisors New York $4.86B AUM 34.09% 1-Year Est. Return

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Solas Capital Management Darien, Connecticut $174M AUM 6.33% 1-Year Est. Return

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

United Services Automobile Association San Antonio, Texas $851M AUM 5.13% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Oxford Asset Management Oxford, United Kingdom $232M AUM 31% 1-Year Est. Return

Zebra Capital Management's FENC Position: Q2 2019 in Review

Zebra Capital Management sold out of Fennec Pharmaceuticals (FENC) in Q2 2019, closing a stake of 17,568 shares — an estimated $85K sold.

Zebra Capital Management first reported a position in FENC in Q4 2018 and held it in 2 quarters. The position peaked at $112K in Q4 2018. 30 funds tracked by Wall St. Rank hold FENC as of Q2 2019.

Zebra Capital Management reported no remaining Fennec Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
Zebra Capital Management sold 17,568 Fennec Pharmaceuticals shares in Q2 2019, an estimated $85K.
Zebra Capital Management first reported a position in Fennec Pharmaceuticals in Q4 2018 and held it in 2 quarters.
Zebra Capital Management's Fennec Pharmaceuticals position peaked at $112K in Q4 2018.
30 funds tracked by Wall St. Rank held Fennec Pharmaceuticals as of Q2 2019.

Based on Zebra Capital Management's 13F filing for Q2 2019, filed 14 Aug 2019.